Shenandoah’s manufacturing portfolio includes its cell therapy grade line of cytokines and growth factors produced following current good manufacturing practice guidelines in the company’s new ISO 9002:2015 certified facility. Fujifilm said that Shenanondoah Biotechnology’s recombinant protein portfolio complements its line of serum-free and cell culture media.

Financial details of the deal were not disclosed.

Atara Biotherapeutics partners with Fujifilm on cell therapy manufacturing
Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm under which Fujifilm will acquire Atara's T-cell operations and manufacturing...

Fujifilm Irvine Scientific launches European manufacturing facility
Fujifilm Irvine Scientific has launched a new manufacturing facility in Tilburg, the Netherlands. The facility provides life science manufacturing, which...

Fujifilm Irvine Scientific establishes innovation center in China
Fujifilm Irvine Scientific will establish an innovation and collaboration Center in Suzhou New District, China. The new center will allow Fujifilm to...

With Hitachi deal done, Fujifilm sets sights on healthcare growth
Fresh off its acquisition of Hitachi's medical imaging business, Japanese industrial giant Fujifilm on July 1 rebranded its healthcare subsidiaries in...

Fujifilm secures funding, signs lease for new research/manufacturing center
Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and...